Figure 1.
Mechanisms of VTE in patients with lymphoma receiving CAR T-cell therapy. HLH, hemophagocytic lymphohistiocytosis. Created with BioRender.com and adapted from elsewhere.11-13

Mechanisms of VTE in patients with lymphoma receiving CAR T-cell therapy. HLH, hemophagocytic lymphohistiocytosis. Created with BioRender.com and adapted from elsewhere.11-13 

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal